U.S. markets open in 6 hours 18 minutes
  • S&P Futures

    3,798.00
    +7.50 (+0.20%)
     
  • Dow Futures

    30,838.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    13,054.75
    +69.25 (+0.53%)
     
  • Russell 2000 Futures

    2,142.60
    -4.70 (-0.22%)
     
  • Crude Oil

    53.39
    +0.41 (+0.77%)
     
  • Gold

    1,854.70
    +14.50 (+0.79%)
     
  • Silver

    25.61
    +0.29 (+1.15%)
     
  • EUR/USD

    1.2155
    +0.0022 (+0.18%)
     
  • 10-Yr Bond

    1.0920
    0.0000 (0.00%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3664
    +0.0030 (+0.22%)
     
  • USD/JPY

    103.7890
    -0.1030 (-0.10%)
     
  • BTC-USD

    35,624.14
    -270.11 (-0.75%)
     
  • CMC Crypto 200

    706.68
    -8.52 (-1.19%)
     
  • FTSE 100

    6,712.95
    0.00 (0.00%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

Translate Bio to Participate in Upcoming Investor Conferences

Translate Bio, Inc.
·2 min read

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

  • Jefferies Virtual London Healthcare Conference: John Schroer, chief financial officer, will present a corporate overview at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 a.m. ET.

  • Evercore ISI HealthCONx Conference: Ronald Renaud, chief executive officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 2:15 p.m. ET.

A live webcast of the sessions will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio believes that mRNA can be delivered to target tissues via multiple routes of administration and, consequently, its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Contacts for Translate Bio

Investors
Teri Dahlman
tdahlman@translate.bio
617-817-8655

Media
Maura Gavaghan
mgavaghan@translate.bio
617-233-1154